Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBay Pharmaceuticals has been awarded a cash grant of $244,479 under the US Government's Qualifying Therapeutic Discovery Project (QTDP) program, for its program to treat Impetigo.
Subscribe to our email newsletter
The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.
NovaBay is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells.